PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19879324-5	2010	TNF-alpha-induced phosphorylations of both p44/p42 MAP kinase and Akt were markedly enhanced by rapamycin.	Sirolimus	96-105	mitogen-activated protein kinase 3	Mus musculus	43-46	
18165767-9	2007	Rapamycin treatment of islets in vitro resulted in reduced p70s6k phosphorylation, which was paralleled by increased ERK1/2 phosphorylation.	Sirolimus	0-9	mitogen-activated protein kinase 3	Mus musculus	117-123	
10334873-7	1999	Ethanol-plus-S1P-induced DNA synthesis was partially inhibited by both PD 98059 (50 microM) and rapamycin (10 nM), inhibitors of p42/p44 MAP kinase kinase and mTOR/p70 S6 kinases, respectively.	Sirolimus	96-105	mitogen-activated protein kinase 3	Mus musculus	133-136	
32747435-7	2020	Inhibition of mTor signaling by rapamycin partially rescued Erk1/2 depletion-induced intestinal defects and significantly prolonged mutant mice life span.	Sirolimus	32-41	mitogen-activated protein kinase 3	Mus musculus	60-66	
30904162-8	2019	Mechanistic studies showed that rapamycin attenuates TAA progression by inhibiting miR-126-3p through ERK1/2 inactivation.	Sirolimus	32-41	mitogen-activated protein kinase 3	Mus musculus	102-108	
30074157-0	2018	Rapamycin Treatment Attenuates Angiotensin II -induced Abdominal Aortic Aneurysm Formation via VSMC Phenotypic Modulation and Down-regulation of ERK1/2 Activity.	Sirolimus	0-9	mitogen-activated protein kinase 3	Mus musculus	145-151	
28450279-7	2017	Cultured mouse podocytes were treated with the autophagy activators, rapamycin or Earle"s balanced salt solution (EBSS), for 48 h. Both rapamycin and EBSS significantly decreased p62 protein levels, increased ERK1/2 activation by phosphorylating pTpY185/187, and increased mRNA and protein expressions of PRR.	Sirolimus	136-145	mitogen-activated protein kinase 3	Mus musculus	209-215	
28450279-11	2017	ERK1/2 inhibitor U0126 significantly attenuated mRNA and protein expressions of PRR in podocytes treated with rapamycin.	Sirolimus	110-119	mitogen-activated protein kinase 3	Mus musculus	0-6	
24753052-8	2014	Overexpression of these ovulatory genes was associated with hyper-activation of extracellular signal-regulated kinase 1/2 (ERK1/2), which occurred in response to inhibition of MTOR with rapamycin and suggested that MTOR may function as a negative regulator of the mitogen-activated protein kinase (MAPK) pathway.	Sirolimus	186-195	mitogen-activated protein kinase 3	Mus musculus	80-121	
24753052-8	2014	Overexpression of these ovulatory genes was associated with hyper-activation of extracellular signal-regulated kinase 1/2 (ERK1/2), which occurred in response to inhibition of MTOR with rapamycin and suggested that MTOR may function as a negative regulator of the mitogen-activated protein kinase (MAPK) pathway.	Sirolimus	186-195	mitogen-activated protein kinase 3	Mus musculus	123-129	
19285553-5	2009	Rapamycin also enhanced the LPS-induced NF-kappaB transactivation as determined by a reporter assay, phosphorylation of the p38 and Erk1/2 MAPKs, and counteracted PPAR activity.	Sirolimus	0-9	mitogen-activated protein kinase 3	Mus musculus	132-138	
32878509-8	2020	In addition, rapamycin scavenged the cellular reactive oxygen species (ROS) and diminished p-JNK, p-ERK1/2 and p-p38 expression of MAPK pathways in RAW264.7 cells infected with P. aeruginosa.	Sirolimus	13-22	mitogen-activated protein kinase 3	Mus musculus	100-106	
28373901-9	2017	Rapamycin induced phosphorylation of ERK1/2 but inhibited p38 phosphorylation.	Sirolimus	0-9	mitogen-activated protein kinase 3	Mus musculus	37-43